Stokes Family Office »

Black Diamond Therapeutics shares owned by Stokes Family Office

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Stokes Family Office from 13F filings

Historical chart of Stokes Family Office investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Stokes Family Office consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Stokes Family Office

Quarter filed Position value Share count Share price at filing
2025-12-31 $27k 11k 2.43

More positions owned by Stokes Family Office

Vanguard Specialized Funds Div App Etf (VIG)
Apple (AAPL)
Alphabet Cap Stk Cl C (GOOG)
Ishares Tr S&p 500 Val Etf (IVE)
Microsoft Corporation (MSFT)
Ishares Tr S&p 500 Grwt Etf (IVW)
Ishares Tr Core Univrsl Usd (IUSB)
Blackrock Etf Trust Ishares Us Equit (DYNF)
Schwab Strategic Tr Int-trm U.s Tres (SCHR)
Ishares Tr Core S&p Ttl Stk (ITOT)
Vanguard Index Fds Total Stk Mkt (VTI)
Ishares Tr S&p 100 Etf (OEF)
Schwab Strategic Tr Intl Eqty Etf (SCHF)
Ishares Emng Mkts Eqt (EMGF)
JPMorgan Chase & Co. (JPM)

View all positions for Stokes Family Office

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
NEA Management Company
Vanguard Group
Acadian Asset Management
Marshall Wace
Siren
Arrowstreet Capital, Limited Partnership
Jane Street
Renaissance Technologies
BlackRock
Vestal Point Capital
Dimensional Fund Advisors
Millennium Management
Connor, Clark & Lunn Investment Management
AWM Investment Company

View all funds holding Black Diamond Therapeutics